TIGENIX news, videos and press releases - Page 2
For more news please use our advanced search feature.
TIGENIX - More news...
TIGENIX - More news...
- Transparency notification pursuant to Article 14 of the Law of May 2, 2007
- TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform
- Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn's disease
- Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae
- Transparency Information
- JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix
- TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting
- TiGenix announces approval of trade name for lead development candidate Cx601 in Europe
- TiGenix announces partial conversion of bonds
- TiGenix strengthens European IP protection around lead development program Cx601
- TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure
- TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601
- TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting
- TiGenix to host Analyst and Investor Event in New York City
- TiGenix to participate and present at key investor and business development meetings
- TiGenix Business and Financial Update for the First Half 2017
- TiGenix strengthens US operations with senior appointments
- TiGenix obtains commercial production license for expanded manufacturing facility
- Transparency Information
- TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland
- Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients
- TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn's Disease and Ulcerative Colitis
- TiGenix Launches Global Phase III Trial for Cx601
- TiGenix announces final equity payment for cardiac platform acquisition
- TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York
- TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure
- CONVENING NOTICE TO THE EXTRAORDINARY SHAREHOLDERS' MEETING TO BE HELD ON 1 JUNE 2017
- TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas
- TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York
- TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week
